{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T17:58:00Z","timestamp":1766599080218,"version":"3.48.0"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T00:00:00Z","timestamp":1757635200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemistry and Biophysics Reports"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.bbrep.2025.102269","type":"journal-article","created":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T07:39:14Z","timestamp":1758613154000},"page":"102269","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Characterization of adalimumab Fab variants with the CH1 domain replaced by the C\u03b11 domain of IgA"],"prefix":"10.1016","volume":"44","author":[{"given":"Rara","family":"Sugimoto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hitomi","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5969-8138","authenticated-orcid":false,"given":"Masato","family":"Kiyoshi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akiko","family":"Ishii-Watabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoko","family":"Oda-Ueda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takatoshi","family":"Ohkuri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbrep.2025.102269_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12929-019-0592-z","article-title":"Development of therapeutic antibodies for the treatment of diseases","volume":"27","author":"Lu","year":"2020","journal-title":"J. Biomed. Sci."},{"key":"10.1016\/j.bbrep.2025.102269_bib2","doi-asserted-by":"crossref","first-page":"2789","DOI":"10.1016\/j.cell.2022.05.029","article-title":"Designing antibodies as therapeutics","volume":"185","author":"Carter","year":"2022","journal-title":"Cell"},{"key":"10.1016\/j.bbrep.2025.102269_bib3","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.3892\/ijo.2015.3210","article-title":"Feasibility study of the fab fragment of a monoclonal antibody against tissue factor as a diagnostic tool","volume":"47","author":"Tsumura","year":"2015","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.bbrep.2025.102269_bib4","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.pdpdt.2006.03.012","article-title":"Fab fragment labeled with ICG-Derivative for detecting digestive tract cancer","volume":"3","author":"Yano","year":"2006","journal-title":"Photodiagnosis Photodyn. Ther."},{"key":"10.1016\/j.bbrep.2025.102269_bib5","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1111\/febs.14991","article-title":"Biophysical characterization and single-chain Fv construction of a neutralizing antibody to measles virus","volume":"287","author":"Tadokoro","year":"2020","journal-title":"FEBS J."},{"key":"10.1016\/j.bbrep.2025.102269_bib6","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1080\/07388551.2024.2342969","article-title":"Escherichia coli and pichia pastoris: microbial cell-factory platform for -full-length IgG production","volume":"45","author":"Krishna","year":"2025","journal-title":"Crit. Rev. Biotechnol."},{"key":"10.1016\/j.bbrep.2025.102269_bib7","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/980250","article-title":"scFv antibody: principles and clinical application","author":"Ahmad","year":"2012","journal-title":"Clin. Dev. Immunol."},{"key":"10.1016\/j.bbrep.2025.102269_bib8","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1111\/j.1476-5381.2009.00190.x","article-title":"Therapeutic antibodies: successes, limitations and hopes for the future","volume":"157","author":"Chames","year":"2009","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.bbrep.2025.102269_bib9","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2022.2153410","article-title":"Antibodies to watch in 2023","volume":"15","author":"Kaplon","year":"2023","journal-title":"MAbs"},{"key":"10.1016\/j.bbrep.2025.102269_bib10","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1159\/000510251","article-title":"When therapeutic IgA antibodies might come of Age","volume":"106","author":"Sterlin","year":"2021","journal-title":"Pharmacology"},{"key":"10.1016\/j.bbrep.2025.102269_bib11","doi-asserted-by":"crossref","first-page":"6856","DOI":"10.3390\/ijms25136856","article-title":"Stability engineering of recombinant secretory IgA","volume":"25","author":"G\u00f6ritzer","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bbrep.2025.102269_bib12","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1038\/s41467-019-13992-8","article-title":"IgA subclasses have different effector functions associated with distinct glycosylation profiles","volume":"11","author":"Steffen","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bbrep.2025.102269_bib13","first-page":"221","article-title":"IgA, IgA receptors, and their anti-inflammatory properties","volume":"382","author":"Mkaddem","year":"2014","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"10.1016\/j.bbrep.2025.102269_bib14","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1002\/art.39142","article-title":"Reversal of arthritis by human monomeric IgA through the receptor-mediated SH2 domain-containing phosphatase 1 inhibitory pathway","volume":"67","author":"Rossato","year":"2015","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.bbrep.2025.102269_bib15","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.ymthe.2024.01.025","article-title":"Recombinant neutralizing secretory IgA antibodies for preventing mucosal acquisition and transmission of SARS-CoV-2","volume":"32","author":"G\u00f6ritzer","year":"2024","journal-title":"Mol. Ther."},{"key":"10.1016\/j.bbrep.2025.102269_bib16","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1093\/jb\/mvad047","article-title":"Analysis of thermostability for seven phe to Ala and six Pro to Gly mutants in the Fab constant region of adalimumab","volume":"174","author":"Yoshikawa","year":"2023","journal-title":"J. Biochem."},{"key":"10.1016\/j.bbrep.2025.102269_bib17","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.bbrc.2017.10.140","article-title":"A novel engineered interchain disulfide bond in the constant region enhances the thermostability of adalimumab Fab","volume":"495","author":"Nakamura","year":"2018","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.bbrep.2025.102269_bib18","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-92225-9","article-title":"A comprehensive analysis of novel disulfide bond introduction site into the constant domain of human Fab","volume":"11","author":"Nakamura","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bbrep.2025.102269_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbrc.2024.149592","article-title":"Stabilization of adalimumab Fab through the introduction of disulfide bonds between the variable and constant domains","volume":"700","author":"Yoshikawa","year":"2024","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.bbrep.2025.102269_bib20","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/j.bbrc.2018.06.071","article-title":"Introduction of a glycosylation site in the constant region decreases the aggregation of adalimumab Fab","volume":"503","author":"Nakamura","year":"2018","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.bbrep.2025.102269_bib21","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1159\/000235071","article-title":"Biological role of different antibody classes","volume":"90","author":"Spiegelberg","year":"1989","journal-title":"Int. Arch. Allergy Appl. Immunol."},{"key":"10.1016\/j.bbrep.2025.102269_bib22","doi-asserted-by":"crossref","first-page":"S41","DOI":"10.1016\/j.jaci.2009.09.046","article-title":"Structure and function of immunoglobulins","volume":"125","author":"Schroeder","year":"2010","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.bbrep.2025.102269_bib23","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.818736","article-title":"Sialylation as an important regulator of antibody function","volume":"13","author":"Vattepu","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bbrep.2025.102269_bib24","doi-asserted-by":"crossref","first-page":"24525","DOI":"10.1074\/jbc.M112.369744","article-title":"Engineering an improved IgG4 molecule with reduced disulfide bond heterogeneity and increased Fab domain thermal stability","volume":"287","author":"Peters","year":"2012","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bbrep.2025.102269_bib25","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1107\/S0907444912048664","article-title":"Structure of a human IgA1 Fab fragment at 1.55 \u00c5 resolution: potential effect of the constant domains on antigen-affinity modulation","volume":"69","author":"Correa","year":"2013","journal-title":"Acta Crystallogr. D Biol. Crystallogr."},{"key":"10.1016\/j.bbrep.2025.102269_bib26","article-title":"Binding induced conformational changes of proteins correlate with their intrinsic fluctuations: a case study of antibodies","volume":"17","author":"Keskin","year":"2007","journal-title":"BMC Struct. Biol."},{"key":"10.1016\/j.bbrep.2025.102269_bib27","doi-asserted-by":"crossref","first-page":"7237","DOI":"10.1021\/bi800374q","article-title":"Exploring the energy landscape of antibody-antigen complexes: protein dynamics, flexibility, and molecular recognition","volume":"47","author":"Thielges","year":"2008","journal-title":"Biochemistry"},{"key":"10.1016\/j.bbrep.2025.102269_bib28","first-page":"67","article-title":"Allosteric control of antibody-prion recognition through oxidation of a disulfide bond between the CH and CL chains","volume":"30","author":"Zhao","year":"2017","journal-title":"Protein Eng. Des. Sel."},{"key":"10.1016\/j.bbrep.2025.102269_bib29","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.811632","article-title":"Structural basis of antibody conformation and stability modulation by framework somatic hypermutation","volume":"12","author":"Sheng","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bbrep.2025.102269_bib30","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1107\/S0907444912048664","article-title":"Structure of a human IgA1 fab fragment at 1.55 \u00c5 resolution: potential effect of the constant domains on antigen-affinity modulation","volume":"69","author":"Correa","year":"2013","journal-title":"Acta Crystallogr. D. Biol. Crystallogr."}],"container-title":["Biochemistry and Biophysics Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405580825003565?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405580825003565?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T17:53:08Z","timestamp":1766598788000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405580825003565"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":30,"alternative-id":["S2405580825003565"],"URL":"https:\/\/doi.org\/10.1016\/j.bbrep.2025.102269","relation":{},"ISSN":["2405-5808"],"issn-type":[{"type":"print","value":"2405-5808"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Characterization of adalimumab Fab variants with the CH1 domain replaced by the C\u03b11 domain of IgA","name":"articletitle","label":"Article Title"},{"value":"Biochemistry and Biophysics Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbrep.2025.102269","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"102269"}}